Jayanth Sridhar, MD

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp share takeaways for health care professionals taking care of patients with geographic atrophy and earlier stages of age-related macular degeneration.

Eleonora M. Lad, MD, PhD, shares how advances in ocular imaging, including AI tools, can improve diagnosis of geographic atrophy going forward.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss the need to improve the referral process through educating physicians about geographic atrophy.

A panel of experts discuss what clinics need to consider when introducing new geographic atrophy treatments in their practice.

Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp share insights to ensure adherence to therapy once started.

An expert panel discusses the role of complement C3 vs C5 therapies and provides guidance for treatment selection in geographic atrophy.

Drs Eleonora M. Lad and Nancy M. Holekamp review other emerging treatment options for geographic atrophy.

A panel of experts comments on the safety data of pegcetacoplan in geographic atrophy and their approach to monitoring patients.

Eleonora M. Lad, MD, PhD, shares her approach to treating subfoveal lesions and geographic atrophy in both eyes.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss pegcetacoplan dose frequency in treating geographic atrophy.

A panel of experts discuss clinical data with pegcetacoplan for treatment of geographic atrophy.

An expert panel provides an overview of pathophysiological changes in geographic atrophy, ongoing research and promising new treatment options.

Jaynath R. Sridhar, MD, shares insights into managing geographic atrophy in his clinic given that there is no FDA-approved treatment.

David R. Lally, MD, and Jayanth Sridhar, MD, comment on the use of imaging tools to for diagnosis and measuring progression of geographic atrophy.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss progression of geographic atrophy and what should be discussed with patients.

A panel of experts shares their thoughts on communicating with patients with mild, intermediate and neovascular age-related macular degeneration about treatment, compliance, and the potential to develop geographic atrophy.

Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp discuss numerous ways geographic atrophy can impact the caregiver’s quality of life.

An expert panel reviews the burden of geographic atrophy, and the various tools patients can use to help manage that burden.

Jayanth Sridhar, MD, Nancy M. Holekamp, MD, FASRS, and David R. Lally, MD, share their thoughts on measuring visual changes to determine how their patients’ geographic atrophy is progressing.

Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp provide an overview of age-related macular degeneration and risk of developing geographic atrophy (GA).

Expert perspectives on the ongoing unmet needs in the management of macular edema following retinal vein occlusion.

Experts reflect on the role of steroids in macular edema following retinal vein occlusion and discuss the limited benefit of combination therapy.

Two experts discuss real-world treatment and observation of patients with macular edema after retinal vein occlusion.

Experts consider when they would use specific VEGF inhibitors for patients with macular edema following retinal vein occlusion.

Shared insight on clinical trial data in macular edema following retinal vein occlusion that support use of VEGF inhibition.

A broad scope of treatment options used in the management of macular edema following retinal vein occlusion.

A brief review of how the COVID-19 pandemic has impacted the identification of retinal vein occlusion for physicians and patients.

Comprehensive insight on optimal work-up and diagnostic testing for patients with retinal vein occlusion.

Experts define retinal vein occlusion and discuss risk factors, diagnostic testing, prognosis, and lifestyle modifications prevalent in the current paradigm.